<DOC>
	<DOC>NCT01661790</DOC>
	<brief_summary>To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion, Malignant</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients with advanced recurrent or progressive NSCLC proven cytohistologically Karnofsky performance status (KPS) ≥60 Life expectancy ≥ 2 months No history of severe diseases of major organs including liver, heart, and kidney No previous intrapleural therapy Written informed consent Active thoracic cavity or systemic bleeding Active pleural or systemic infection. Known sensitivity to Bevacizumab or Cisplatin Refusal to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Bevacizumab;</keyword>
	<keyword>non-small cell lung cancer;</keyword>
	<keyword>malignant pleural effusion;</keyword>
	<keyword>intrapleural administration</keyword>
</DOC>